# OnCo record oxaliplatin (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/oxaliplatin/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "oxaliplatin" ;
  schema:name "Oxaliplatin"@en ;
  schema:description "The platinum drug that works in bowel cancer where cisplatin does not, the 'OX' in FOLFOX and CAPOX; its cost is nerve damage in hands and feet."@en ;
  schema:url <https://onco.cc/drugs/oxaliplatin/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Oxaliplatin> ;
  owl:sameAs <http://www.wikidata.org/entity/Q422327> ;
  schema:citation <https://doi.org/10.1056/NEJMoa032709>, <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=oxaliplatin> ;
  onco:status "approved" ;
  onco:tag "gap-fill", "generic", "who-essential" ;
  onco:modality "Third-generation platinum (DACH-platinum)" ;
  schema:alternateName "Eloxatin" ;
  onco:approval "EU 1996: Metastatic colorectal cancer", "US 2002: Metastatic colorectal cancer with 5-FU/LV", "US 2004: Adjuvant stage III colon cancer" ;
  onco:acceleratedApproval "US 2002-08-09: In combination with infusional 5-FU/LV for metastatic color or rectal carcinoma that progressed during or within 6 months of completion of first-line therapy with bolus 5 -FU/LV and irinotectan" ;
  onco:acceleratedApprovalConfirmed "US 2004-01-09: In combination with infusional 5-FU/LV for metastatic color or rectal carcinoma that progressed during or within 6 months of completion of first-line therapy with bolus 5 -FU/LV and irinotectan" ;
  onco:cancers <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/gastric/>, <https://onco.cc/cancers/esophageal/>, <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/appendiceal/>, <https://onco.cc/cancers/mucinous-ovarian-cancer/> ;
  onco:technologies <https://onco.cc/technologies/platinum/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:companies <https://onco.cc/companies/sanofi/> ;
  onco:trials <https://onco.cc/trials/rapido/>, <https://onco.cc/trials/nct05300269/>, <https://onco.cc/trials/nct07554521/>, <https://onco.cc/trials/nct05980481/>, <https://onco.cc/trials/nct06469944/>, <https://onco.cc/trials/nct06155383/>, <https://onco.cc/trials/nct07415031/>, <https://onco.cc/trials/nct06901531/>, <https://onco.cc/trials/nct05771480/>, <https://onco.cc/trials/nct06247956/>, <https://onco.cc/trials/nct06951503/>, <https://onco.cc/trials/nct06771622/>, <https://onco.cc/trials/nct05945823/>, <https://onco.cc/trials/nct07056777/>, <https://onco.cc/trials/nct06662786/>, <https://onco.cc/trials/nct03505320/>, <https://onco.cc/trials/nct05329766/>, <https://onco.cc/trials/nct05144854/>, <https://onco.cc/trials/nct07582315/>, <https://onco.cc/trials/nct07606599/>, <https://onco.cc/trials/nct07431281/>, <https://onco.cc/trials/nct03478488/>, <https://onco.cc/trials/nct07315750/>, <https://onco.cc/trials/nct04379596/>, <https://onco.cc/trials/nct06806033/>, <https://onco.cc/trials/nct06780111/>, <https://onco.cc/trials/spotlight-glow/>, <https://onco.cc/trials/nct06854445/>, <https://onco.cc/trials/mountaineer/>, <https://onco.cc/trials/nct07390383/>, <https://onco.cc/trials/nct06825494/>, <https://onco.cc/trials/nct07238283/>, <https://onco.cc/trials/nct07522151/>, <https://onco.cc/trials/nct07730021/>, <https://onco.cc/trials/nct07283367/>, <https://onco.cc/trials/nct05239741/>, <https://onco.cc/trials/nct06741644/>, <https://onco.cc/trials/nct05671822/>, <https://onco.cc/trials/nct05859750/>, <https://onco.cc/trials/nct06256328/>, <https://onco.cc/trials/nct04919226/>, <https://onco.cc/trials/nct04725994/>, <https://onco.cc/trials/mosaic/>, <https://onco.cc/trials/idea-collaboration/>, <https://onco.cc/trials/prodige-7/>, <https://onco.cc/trials/colopec/>, <https://onco.cc/trials/prophylochip/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-mosaic-oxaliplatin-adjuvant-colon-nejm-2004/> .